Post
Weekly insulin analogues approaching approval could herald change
Upcoming weekly insulin candidates can reduce the injection burden on patients with diabetes and ease the load on healthcare resources, …
“Lack of harmonisation in Europe” hindering gene therapy growth
Amid a US regulatory landscape promoting collaboration in cell and gene therapy development, SpliceBio’s CEO Miquel Vila-Perelló has questioned why …
Chemomab touts study confirming CCL24 link to systemic sclerosis severity
Clinical-stage biotech Chemomab Therapeutics has announced the publication of a study highlighting that high serum CCL24 levels are linked to …
OncoX inks licensing deal worth over $26m for NSCLC therapy
US-based ABVC BioPharma has sold the rights to its botanical drug extract therapy, BLEX 404, for the treatment of non-small …
Inflammation among current dementia research focus, says Alchemab CSO
Inflammation, cell metabolism and neuronal health are current key areas of focus for dementia researchers, according to Jane Osbourn, chief …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Hodgkin Lymphoma: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Hodgkin Lymphoma. According to …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Melanoma: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Melanoma. According to GlobalData, …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Head And Neck Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Head And Neck Cancer. …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Cervical Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Cervical Cancer. According to …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Ovarian Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Ovarian Cancer. According to …
(Dexborneol + edaravone) by Neurodawn Pharmaceutical for Acute Ischemic Stroke: Likelihood of Approval
(Dexborneol + edaravone) is under clinical development by Neurodawn Pharmaceutical and currently in Phase I for Acute Ischemic Stroke. According …
Weekly insulin analogues approaching approval could herald change
Upcoming weekly insulin candidates can reduce the injection burden on patients with diabetes and ease the load on healthcare resources, …
“Lack of harmonisation in Europe” hindering gene therapy growth
Amid a US regulatory landscape promoting collaboration in cell and gene therapy development, SpliceBio’s CEO Miquel Vila-Perelló has questioned why …
Chemomab touts study confirming CCL24 link to systemic sclerosis severity
Clinical-stage biotech Chemomab Therapeutics has announced the publication of a study highlighting that high serum CCL24 levels are linked to …
OncoX inks licensing deal worth over $26m for NSCLC therapy
US-based ABVC BioPharma has sold the rights to its botanical drug extract therapy, BLEX 404, for the treatment of non-small …